Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA’s PRIME Offers Hope To Advanced Therapies As More Get A “Yes”

Executive Summary

Juno Therapeutics and bluebird bio are the latest companies to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme with their advanced therapy medicinal products. ATMPs are now the most common type of product on the scheme, and help is coming for developers trying to navigate Europe’s notoriously challenging ATMP framework.

You may also be interested in...



Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy

Bluebird Bio and Celgene have secured a place on both the EMA’s PRIME scheme and the US FDA’s breakthrough therapy designation program for their multiple myeloma CAR-T therapy, bb2121. Meanwhile, Bluebird talks about how “incredibly helpful” PRIME has been with the development of LentiGlobin for beta-thalassemia.

EMA's Action Plan To Support ATMPs Expected In Jan 2017

The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.

EMA's PRIME Scheme: Why Nearly Four Out Of Five Fail To Make The Grade

The European Medicines Agency has told the Pink Sheet about the common mistakes companies are making in their bid to enter its popular priority medicines (PRIME) scheme. Meanwhile, applicants that have succeeded in getting accepted for the scheme talk of "convivial" and "efficient" discussions with the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel